INmune Bio Inc., a clinical-stage company specializing in inflammation and immunology, has announced promising results from a study involving their drug XPro™. The study, conducted in collaboration with Kirsty Dixon, PhD, Associate Professor of Surgery at Virginia Commonwealth University, was presented at the Keystone Symposia's Neurodegeneration section. The findings indicate that XPro™, a next-generation inhibitor of tumor necrosis factor (TNF), effectively reduces amyloid deposition and enhances brain function in an animal model of Alzheimer's disease post-traumatic brain injury $(TBI)$. These results suggest potential benefits in treating Alzheimer's-like pathology and preserving cognitive function in patients with traumatic brain injuries. The drug is currently in clinical trials and could offer a novel approach to addressing neuroinflammation and its effects on neurological health.